File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12072-024-10732-z
- Scopus: eid_2-s2.0-85209718693
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
Title | APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 |
---|---|
Authors | Lau, GeorgeObi, ShuntaroZhou, JianTateishi, RyosukeQin, ShukuiZhao, HaitaoOtsuka, MotoyukiOgasawara, SadahisaGeorge, JacobChow, Pierce K.H.Cai, JianqiangShiina, ShuichiroKato, NaoyaYokosuka, OsamuOura, KyokoYau, ThomasChan, Stephen L.Kuang, MingUeno, YoshiyukiChen, MinshanCheng, Ann LiiCheng, GregoryChuang, Wan LongBaatarkhuu, OidovBi, FengDan, Yock YoungGani, Rino A.Tanaka, AtsushiJafri, WasimJia, Ji DongKao, Jia HorngHasegawa, KiyoshiLau, PatrickLee, Jeong MinLiang, JunLiu, ZhenwenLu, YinyingPan, HongmingPayawal, Diana A.Rahman, SalimurSeong, JinsilShen, FengShiha, GamalSong, TianqiangSun, Hui ChuanMasaki, TsutomuSirachainan, EkaphopWei, LaiYang, Jin MoSallano, Jose D.Zhang, YanqiaoTanwandee, TawesakDokmeci, AKadirZheng, Shu SenFan, JiaFan, Sheung TatSarin, Shiv KumarOmata, Masao |
Keywords | Guidelines Hepatocellular carcinoma Systemic therapy The Asian Pacific Association for the study of the liver |
Issue Date | 1-Dec-2024 |
Publisher | Springer |
Citation | Hepatology International, 2024, v. 18, n. 6, p. 1661-1683 How to Cite? |
Abstract | In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia–Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored? |
Persistent Identifier | http://hdl.handle.net/10722/353790 |
ISSN | 2023 Impact Factor: 5.9 2023 SCImago Journal Rankings: 1.813 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lau, George | - |
dc.contributor.author | Obi, Shuntaro | - |
dc.contributor.author | Zhou, Jian | - |
dc.contributor.author | Tateishi, Ryosuke | - |
dc.contributor.author | Qin, Shukui | - |
dc.contributor.author | Zhao, Haitao | - |
dc.contributor.author | Otsuka, Motoyuki | - |
dc.contributor.author | Ogasawara, Sadahisa | - |
dc.contributor.author | George, Jacob | - |
dc.contributor.author | Chow, Pierce K.H. | - |
dc.contributor.author | Cai, Jianqiang | - |
dc.contributor.author | Shiina, Shuichiro | - |
dc.contributor.author | Kato, Naoya | - |
dc.contributor.author | Yokosuka, Osamu | - |
dc.contributor.author | Oura, Kyoko | - |
dc.contributor.author | Yau, Thomas | - |
dc.contributor.author | Chan, Stephen L. | - |
dc.contributor.author | Kuang, Ming | - |
dc.contributor.author | Ueno, Yoshiyuki | - |
dc.contributor.author | Chen, Minshan | - |
dc.contributor.author | Cheng, Ann Lii | - |
dc.contributor.author | Cheng, Gregory | - |
dc.contributor.author | Chuang, Wan Long | - |
dc.contributor.author | Baatarkhuu, Oidov | - |
dc.contributor.author | Bi, Feng | - |
dc.contributor.author | Dan, Yock Young | - |
dc.contributor.author | Gani, Rino A. | - |
dc.contributor.author | Tanaka, Atsushi | - |
dc.contributor.author | Jafri, Wasim | - |
dc.contributor.author | Jia, Ji Dong | - |
dc.contributor.author | Kao, Jia Horng | - |
dc.contributor.author | Hasegawa, Kiyoshi | - |
dc.contributor.author | Lau, Patrick | - |
dc.contributor.author | Lee, Jeong Min | - |
dc.contributor.author | Liang, Jun | - |
dc.contributor.author | Liu, Zhenwen | - |
dc.contributor.author | Lu, Yinying | - |
dc.contributor.author | Pan, Hongming | - |
dc.contributor.author | Payawal, Diana A. | - |
dc.contributor.author | Rahman, Salimur | - |
dc.contributor.author | Seong, Jinsil | - |
dc.contributor.author | Shen, Feng | - |
dc.contributor.author | Shiha, Gamal | - |
dc.contributor.author | Song, Tianqiang | - |
dc.contributor.author | Sun, Hui Chuan | - |
dc.contributor.author | Masaki, Tsutomu | - |
dc.contributor.author | Sirachainan, Ekaphop | - |
dc.contributor.author | Wei, Lai | - |
dc.contributor.author | Yang, Jin Mo | - |
dc.contributor.author | Sallano, Jose D. | - |
dc.contributor.author | Zhang, Yanqiao | - |
dc.contributor.author | Tanwandee, Tawesak | - |
dc.contributor.author | Dokmeci, AKadir | - |
dc.contributor.author | Zheng, Shu Sen | - |
dc.contributor.author | Fan, Jia | - |
dc.contributor.author | Fan, Sheung Tat | - |
dc.contributor.author | Sarin, Shiv Kumar | - |
dc.contributor.author | Omata, Masao | - |
dc.date.accessioned | 2025-01-24T00:35:52Z | - |
dc.date.available | 2025-01-24T00:35:52Z | - |
dc.date.issued | 2024-12-01 | - |
dc.identifier.citation | Hepatology International, 2024, v. 18, n. 6, p. 1661-1683 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | http://hdl.handle.net/10722/353790 | - |
dc.description.abstract | In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia–Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored? | - |
dc.language | eng | - |
dc.publisher | Springer | - |
dc.relation.ispartof | Hepatology International | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Guidelines | - |
dc.subject | Hepatocellular carcinoma | - |
dc.subject | Systemic therapy | - |
dc.subject | The Asian Pacific Association for the study of the liver | - |
dc.title | APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12072-024-10732-z | - |
dc.identifier.scopus | eid_2-s2.0-85209718693 | - |
dc.identifier.volume | 18 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 1661 | - |
dc.identifier.epage | 1683 | - |
dc.identifier.eissn | 1936-0541 | - |
dc.identifier.issnl | 1936-0533 | - |